{"entity":{"id":"levetiracetam","kind":"drug","name":"Levetiracetam","aka":[],"tldr":"Levetiracetam is an anti-seizure medicine. After CAR-T cell therapy it is the recommended treatment for seizures, and some people at high risk of nerve side effects take it to prevent them.","summary":"The Keppra label covers partial-onset seizures from 1 month of age and, as adjunctive therapy, myoclonic seizures in juvenile myoclonic epilepsy and primary generalised tonic-clonic seizures. SITC 2020: \"To manage seizures in patients treated with CAR T cell therapies, levetiracetam is recommended (LE: 4)\"; there is insufficient evidence for prophylaxis in everyone, but \"in patients deemed to be at high-risk of developing neurotoxicity ... prophylactic levetiracetam may be considered\". The NDA was first approved on 30 November 1999.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Levetiracetam","links":[{"label":"US label (DailyMed): Keppra","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ca9df05-a506-4ec8-a4fe-320f1219ab21"},{"label":"Maus et al., SITC clinical practice guideline on immune effector cell-related adverse events (J Immunother Cancer 2020)","url":"https://doi.org/10.1136/jitc-2020-001511"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["icans"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Keppra","modality":"Antiepileptic (oral, intravenous)","supportive":true,"mechanism":"An antiepileptic that binds synaptic vesicle protein SV2A.","approvals":[{"region":"US","year":1999,"indication":"Partial-onset seizures; adjunctive treatment of myoclonic and primary generalised tonic-clonic seizures","note":"Year is the Keppra NDA 021035 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/levetiracetam/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"term":[{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/"}]}}